These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24998942)

  • 1. Designing and building the next generation of improved vaccine adjuvants.
    Brito LA; O'Hagan DT
    J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
    Shah RR; Hassett KJ; Brito LA
    Methods Mol Biol; 2017; 1494():1-13. PubMed ID: 27718182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.
    Singh M; Ugozzoli M; Kazzaz J; Chesko J; Soenawan E; Mannucci D; Titta F; Contorni M; Volpini G; Del Guidice G; O'Hagan DT
    Vaccine; 2006 Mar; 24(10):1680-6. PubMed ID: 16300864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel adjuvants & delivery vehicles for vaccines development: a road ahead.
    Mohan T; Verma P; Rao DN
    Indian J Med Res; 2013 Nov; 138(5):779-95. PubMed ID: 24434331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvants--essential components of new generation vaccines].
    Dzierzbicka K; Kołodziejczyk AM
    Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
    Chauhan N; Tiwari S; Iype T; Jain U
    Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in vaccine delivery systems.
    O'Hagan DT
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants.
    Spreafico R; Ricciardi-Castagnoli P; Mortellaro A
    Eur J Immunol; 2010 Mar; 40(3):638-42. PubMed ID: 20201020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving vaccines by incorporating immunological coadjuvants.
    Fraser CK; Diener KR; Brown MP; Hayball JD
    Expert Rev Vaccines; 2007 Aug; 6(4):559-78. PubMed ID: 17669010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in vaccine adjuvants for infectious diseases.
    Singh M; Srivastava I
    Curr HIV Res; 2003 Jul; 1(3):309-20. PubMed ID: 15046255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.
    Dey AK; Srivastava IK
    Expert Rev Vaccines; 2011 Feb; 10(2):227-51. PubMed ID: 21105782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in vaccine adjuvants.
    Singh M; O'Hagan DT
    Pharm Res; 2002 Jun; 19(6):715-28. PubMed ID: 12134940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology of TLR-independent vaccine adjuvants.
    De Gregorio E; D'Oro U; Wack A
    Curr Opin Immunol; 2009 Jun; 21(3):339-45. PubMed ID: 19493664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.